Eight K. pneumoniae isolates were received from the Medical Microbiology laboratories of three hospitals in Armenia between January 2019 and August 2019. All isolates were recovered from various clinical specimens (urine, sputum, throat, blood, and stool) of hospitalized patients. The isolates were identified using a matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF-MS) as described previously (59 (link)).
All isolates were tested using a disk diffusion method for susceptibility to a panel of 11 antibiotics, including ampicillin (10 mg), piperacillin-tazobactam (30/6 mg), amoxicillin-clavulanic acid (20 and 10 mg, respectively), ceftazidime (10 mg), cefepime (30 mg), norfloxacin (10 mg), levofloxacin (5 mg), amikacin (30 mg), imipenem (10 mg), meropenem (10 mg), and chloramphenicol (30 mg) (Mast Group, Merseyside, United Kingdom) according to the European Committee on Antimicrobial Susceptibility Testing protocol (EUCAST v.6.0, 2017) (60 ). The antibiotics chosen were those most frequently used in clinical settings in Armenia. Isolates resistant to three or more antibiotic classes were considered multidrug resistant.
All isolates were tested using a disk diffusion method for susceptibility to a panel of 11 antibiotics, including ampicillin (10 mg), piperacillin-tazobactam (30/6 mg), amoxicillin-clavulanic acid (20 and 10 mg, respectively), ceftazidime (10 mg), cefepime (30 mg), norfloxacin (10 mg), levofloxacin (5 mg), amikacin (30 mg), imipenem (10 mg), meropenem (10 mg), and chloramphenicol (30 mg) (Mast Group, Merseyside, United Kingdom) according to the European Committee on Antimicrobial Susceptibility Testing protocol (EUCAST v.6.0, 2017) (60 ). The antibiotics chosen were those most frequently used in clinical settings in Armenia. Isolates resistant to three or more antibiotic classes were considered multidrug resistant.
Free full text: Click here
